[Federal Register Volume 82, Number 98 (Tuesday, May 23, 2017)]
[Notices]
[Pages 23591-23592]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-10518]


=======================================================================
-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-968]


Certain Radiotherapy Systems and Treatment Planning Software, and 
Components Thereof; Commission Determination To Grant a Joint Motion To 
Terminate the Investigation on the Basis of a Settlement Agreement; 
Termination of the Investigation

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission (the ``Commission'') has determined to grant a joint motion 
to terminate the above-captioned investigation based on a settlement 
agreement.

FOR FURTHER INFORMATION, CONTACT: Ron Traud, Office of the General 
Counsel, U.S. International Trade Commission, 500 E Street SW., 
Washington, DC 20436, telephone (202) 205-3427. Copies of non-
confidential documents filed in connection with this investigation are 
or will be available for inspection during official business hours 
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street SW., Washington, DC 20436, 
telephone 202-205-2000. General information concerning the Commission 
may also be obtained by accessing its Internet server (https://www.usitc.gov). The public record for this investigation may be viewed 
on the Commission's electronic docket (EDIS) at https://edis.usitc.gov. 
Hearing-impaired persons are advised that information on this matter 
can be obtained by contacting the Commission's TDD terminal on 202-205-
1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
on October 30, 2015, based on a complaint filed by Varian Medical 
Systems, Inc. of Palo Alto, California; and Varian Medical Systems 
International AG of ZG, Switzerland (collectively, ``Varian''). 80 FR 
66934 (Oct. 30, 2015). The complaint alleges violations of section 337 
of the Tariff Act of 1930, as amended, 19 U.S.C. 1337 (``section 
337''), in the importation into the United States, the sale for 
importation, or the sale within the United States after importation of 
certain radiotherapy systems and treatment planning software, and 
components thereof by reason of infringement of certain claims of U.S. 
Patent Nos. 7,945,021 (``the '021 patent''); 8,116,430 (``the '430 
patent''); 8,867,703 (``the '703 patent''); 7,880,154 (``the '154 
patent''); 7,906,770 (``the '770 patent''); and 8,696,538 (``the '538 
patent''). Id. The notice of investigation named as respondents Elekta 
AB of Stockholm, Sweden; Elekta Ltd. of Crawley, United Kingdom; Elekta 
GmbH of Hamburg, Germany; Elekta Inc. of Atlanta, Georgia; IMPAC 
Medical Systems, Inc. of Sunnyvale, California; Elekta Instrument 
(Shanghai) Limited of Shanghai, China; and Elekta Beijing Medical 
Systems Co. Ltd. of Beijing, China (collectively, ``Elekta''). The 
Office of Unfair Import Investigations (``OUII'') also was named as a 
party to the investigation. Id.
    Prior to the evidentiary hearing, Varian withdrew its allegations 
as to certain patent claims and also added additional claims. See 
Notice of Commission Determination Not to Review an Initial 
Determination Granting a Motion to Amend the Complaint and Notice of 
Investigation (Apr. 4, 2016). Varian proceeded at the evidentiary 
hearing on the following patents and claims: claims 1, 4, 9, and 15 of 
the '021 patent; claims 6 and 18 of the '430 patent; claim 1 of the 
'703 patent; claims 23 and 26 of the '154 patent; claims 61, 67, and 68 
of the '770 patent; and claims 26 and 41 of the '538 patent.
    On October 27, 2016, the administrative law judge (the ``ALJ'') 
issued his final initial determination (the ``Final ID''), which found 
a violation of section 337 by Elekta as to claims 23 and 26 of the '154 
patent; claims 26 and 41 of the '538 patent; and claim 67 of the '770 
patent. The Final ID found no violation of section 337 in connection 
with claim 61 of the '770 patent; claims 1, 4, 9, and 15 of the '021 
patent; claims 6 and 18 of the '430 patent; and claim 1 of the '703 
patent. See Final ID at 462-63. The parties each petitioned for review 
of the Final ID. On January 13, 2017, the Commission determined to 
review the Final ID's conclusion that the claims asserted for 
infringement and/or domestic industry of the '154 patent, the '770 
patent, and the '538 patent are not invalid as obvious. 82 FR 7856 
(Jan. 23, 2017). As to this issue, the Commission remanded the 
investigation to the ALJ. Id. The Commission also determined to review 
the Final ID's determinations regarding (1) the obviousness of the 
asserted claims of the '021 patent, the '430 patent, and the '703 
patent; (2) the claim construction of the claim term ``communications 
network,'' as found in the asserted claims of the '021 and '430 
patents; (3) the anticipation of claim 18 of the '430 patent by the 
Jaffray MICCAI 2001 reference; and (4) the infringement of claim 18 of 
the '430 patent and the asserted claims of the '154, '538, and '770 
patents. Id. On March 31, 2017, the ALJ issued his remand initial 
determination (the ``Remand ID''), finding the claims subject to the 
remand to be nonobvious. Remand ID at 27.
    On April 14, 2017, the private parties filed a Joint Motion to 
Terminate the Investigation Based on a Settlement Agreement (the 
``Motion'') and a confidential and a public version of the settlement 
agreement (the

[[Page 23592]]

``Agreement''). On April 25, 2017, OUII filed a response supporting the 
Motion.
    The Commission has determined that the Motion complies with the 
requirements of section 210.21(b)(1) of the Commission's Rules of 
Practice and Procedure (19 CFR 210.21(b)(1)), and that there are no 
extraordinary circumstances that would prevent the requested 
termination. The Commission also finds that granting the Motion would 
not be contrary to the public interest pursuant to section 210.50(b)(2) 
of the Commission's Rules of Practice and Procedure (19 CFR 
210.50(b)(2)). Accordingly, the Commission hereby grants the Motion. 
This investigation is terminated.
    The authority for the Commission's determination is contained in 
section 337 of the Tariff Act of 1930, as amended (19 U.S.C. 1337), and 
in part 210 of the Commission's Rules of Practice and Procedure (19 CFR 
part 210).

    By order of the Commission.

     Issued: May 18, 2017.
Lisa R. Barton,
Secretary to the Commission.
[FR Doc. 2017-10518 Filed 5-22-17; 8:45 am]
 BILLING CODE 7020-02-P